HIC Capital Group


HUB of Pharma:
in-phisique & in-digital

Meds&components-making plant + B2b-marketplace portal
Support the smart life sciences company – Amazon model for the Indian pharma
eMedhub is a digital life sciences company that plans to converge the digital marketplace with traditional mfg.
Capitalizing on untapped market, eMedhub will become a $1 bn+ company in next 10 yrs. delivering value across the e2e LS Value chain
An intelligent digital B2B marketplace platform connecting across the pharmaceutical value-chain; become first mover in untapped territory
Cutting edge AI-manufacturing of the critical upcoming in- demand pharmaceuticals items located in India
Significant opportunity exists to tap into the rise of Indian pharmaceutical industry, internet penetration and manufacturing across India
Indian pharmaceutical sector is expected to grow to US$ 100 billion by 2025; there will be over 650 million internet users across India by2023
Indian pharmaceutical manufacturing
*Source: InvestinIndia.gov
  • 1
    Largest number of US-FDA compliant Pharma plants (more than 262 including APIs) outside of USA
  • 2
    More than 2000 WHO-GMP approved Pharma Plants, 253 European Directorate of Quality Medicines (EDQM) approved plants
  • 3
    60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different Active Pharmaceutical Ingredients (APIs)
  • 4
    API industry is ranked third largest in the world contributing 57% of APIs to prequalified list of the WHO
  • 5
    Home to more than 3,000 pharma companies with a strong network of over
    10,500 manufacturing facilities

Vision & Plan Overview
Manufacturing business overview: We have identified niche therapeutic segments; includes both high volume and high margin product portfolio; this will expand and evolve as we learn market movement/growth area trends more from our digital platform

Existing network across all national hospitals and 1,000+ AI mfg.
Phase I (2022-2024)
•Intensive Care
•Dermatology & Cosmetology
•Expand Intensive Care
•Nutritional Range (Oral,Enteral & Parenteral)
•Plasma Products
•Gastroenterology - IBS
Phase II (2024-2027)
•Gynecology – IVF
•Oncology – Biosimilars and Supportive Care
Phase III (2027 - 2031)
Strengthen the product portfolio in each segment especially :
•Gastroenterology – Chronic Care
•Gynecology – IVF
•Dermatology & Cosmetology

The request
$225M USD (Total)
Company is looking for $50 mln USD loan as a primary funding request

Apply now

Join us in this journey!
Enter the round of the unique Indian MedTech Hub-project!

Within 2 months we are closing the list in order to aggregate the round the round.
The offer can also expire earlier upon finalisation of the investment amount required.
DISCLAIMER: This landing page has been prepared solely for informational purposes in connection with a possible investment offer of the Company. Any person intending to invest in the Company, when making any investment decisions, should rely only on the information set out in the Company's prospectus and any changes or additions to it. No representations or guarantees are given regarding the accuracy, validity and completeness of the information contained in this landing page, and no person has the right to rely on the content of this page. The information presented here may be updated, supplemented, corrected, confirmed or changed. At the same time, significant changes in the information contained in this page are not excluded. Neither the Company, nor its shareholders, nor any of their affiliates, consultants or representatives are under any obligation to update or update the information contained in this landing page, and any conclusions contained in this page may be changed without any notice.
NOTICE: this page is 'blindlead'. For getting more information about name, founders & other data, please fill in the application form above.
В-304, 24K Sereno, Pancard Club Road, Baner, Pune, India, 411045
HIC Capital Group LLC, 2021-2022.
© All Rights Reserved.
Made on